华蟾素预防和治疗原发性肝癌的临床研究进展  

Clinical Research Progress of Cinobufacini for Prevention and Treatment of Hepatocellular Carcinoma

作　　者：汝文文[1] 张路[1] 王东亮[1,2] 王凤山[2] 唐伟[3] 

机构地区：[1]山东东阿阿胶股份有限公司国家胶类中药工程技术研究中心,山东聊城252201 [2]山东大学药学院,山东济南250012 [3]东京大学附属医院肝胆胰外科

出　　处：《中国药物评价》2014年第2期92-95,共4页Chinese Journal of Drug Evaluation

摘　　要：原发性肝癌是世界范围内常见的恶性肿瘤之一,目前对中晚期肝癌尚无特别有效的治疗措施。华蟾素是我国传统中药材中华大蟾蜍阴干皮经提取加工制成的灭菌水溶液,具有清热解毒、利水消胀、化瘀软坚、消肿止痛等功效,是我国应用较为广泛的一类抗肿瘤中药制剂。临床研究表明,华蟾素对乙型肝炎有一定的抑制作用,可有效地抑制原发性肝癌的发生。同时,利用华蟾素单纯静脉滴注、静脉滴注联合其他药物、静脉滴注联合肝动脉化疗栓塞、肝动脉化疗栓塞治疗及肝内注射等治疗方法,对中晚期肝癌患者也具有较好的疗效。本文对近年来华蟾素预防和治疗原发性肝癌的临床疗效进行综述。Hepatocellular carcinoma（ HCC） is one of the most common malignant neoplasms worldwide,and remains a formidable challenge for clinical therapy. The skin of Bufo bufo gargarizans Cantor has been reported to have antipyretic,detoxicant,diuresis,stasiseliminative,and pus-discharging properties. Cinobufacini（ Huachansu）,an aqueous extract of dried skin of B. bufo gargarizans B. bufo gargarizans Cantor,is a traditional Chinese medicinal preparation widely used in clinical cancer therapy in China. In recent years,attentions have been paid to cinobufacini for the treatment of HCC. These clinical data have demonstrated that cinobufacini is effective against HCC through intravenous drip,drug combination,or other methods. Moreover,cinobufacini is a promising candidate for the treatment of hepatitis B or hepatic fibrosis to prevent the development of HCC. The present review focuses on clinical researches about cinobufacini for prevention and treatment of HCC in recent years.

关 键 词：华蟾素 原发性肝癌 临床研究进展 

分 类 号：R735.7[医药卫生—肿瘤]